Monitoring patients taking methotrexate for hepatotoxicity: Does the standard of care match published guidelines?
- 31 December 1994
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 31 (6) , 969-977
- https://doi.org/10.1016/s0190-9622(94)70266-7
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- The pharmacology of methotrexateJournal of the American Academy of Dermatology, 1991
- Methotrexate side-effectsBritish Journal of Dermatology, 1990
- The Role of Liver Biopsies in Psoriatic Patients Receiving Long-term Methotrexate TreatmentArchives of Dermatology, 1989
- Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patientsSeminars in Arthritis and Rheumatism, 1989
- Liver histology in rheumatoid arthritis patients receiving long‐term methotrexate therapy. A Prospective Study with Baseline and Sequential Biopsy SamplesArthritis & Rheumatism, 1989
- Methotrexate in psoriasis: Revised guidelinesJournal of the American Academy of Dermatology, 1988
- Methotrexate in Rheumatoid ArthritisAnnals of Internal Medicine, 1987
- Hepatotoxicity of prolonged methotrexate therapy for rheumatoid arthritisCleveland Clinic Journal of Medicine, 1985
- Methotrexate for PsoriasisArchives of Dermatology, 1971
- THERAPEUTIC SUPPRESSION OF TISSUE REACTIVITYThe Lancet Healthy Longevity, 1951